- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05460611
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
A Pilot Study Evaluating the Safety and Efficacy of a 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia. The study may enroll up to 10 participants looking for improvement in their hair loss. All participants will have biopsy-proven alopecia before enrollment. There will be two treatment arms with 5 participants in the androgenetic alopecia arm and 5 participants in the scarring alopecia arm. Multiple treatment areas of the scalp may be performed. Each subject will receive up to three treatments. Follow-up visits are planned for months 6, 9, 12, and 15. Standardized photography, hair density measurement of the treated scalp areas will be recorded Pre and Post Treatment at each visit. Measurement outcomes will be compared to baseline. During the initial visit, subjects who meet the study's eligibility criteria will receive the first treatment after signing informed consent form.
For this study, the investigators will use non-ablative HALO laser (1470nm) (Sciton). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The laser creates controlled zones of coagulation within the dermis. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment procedure will consist of topical anesthetic then cleaning of the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide. The U.S. Food and Drug Administration (FDA) has approved the 1470 nm laser for dermatologic purposes.
The follow up phase will consist of clinical assessments including before and after photographs graded by blinded observers and hair density evaluation using Canfield HairMetrix ® device. Subjects are instructed to inform clinical staff after the treatment if they experience any adverse events and will complete patient questionnaires, pain score, and self-assessment of hair growth.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Janet Choi, BS
- Phone Number: (917)680-9907
- Email: janet.choi@einsteinmed.edu
Study Locations
-
-
New York
-
Elmsford, New York, United States, 10523
- Recruiting
- Montefiore Einstein Advanced Care
-
Contact:
- Hailey Konisky, BS
- Phone Number: 518-596-4306
- Email: hailey.konisky@einsteinmed.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss.
- Subject must voluntarily sign and date an IRB approved informed consent form
- Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months
- Able to read, understand and voluntarily provide written informed consent.
- Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regime during the study.
- Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements.
- Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
Exclusion Criteria:
- Subject does not have the capacity to consent to the study
- Subject has other types of alopecia of the scalp like alopecia areata
- Use of minoxidil or 5-alpha reductase inhibitors (i.e., finasteride, dutasteride) 3 months prior to screening date.
- History of intralesional steroid injections to the scalp in the last 12 months
- Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject.
- Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months.
- Allergy or history of prior reaction to lidocaine
- History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months.
History or current use of the following prescription medications:
i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months
- Smoking or vaping in the past 12 months.
- History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders.
- History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Androgenetic Alopecia
The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton.
Each laser treatment will take approximately 10 to 15 minutes per subject to target androgenetic alopecia.
|
Patients will be treated with the 1470nm non-ablative laser.
|
Experimental: Scarring Alopecia
The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton.
Each laser treatment will take approximately 10 to 15 minutes per subject to target scarring alopecia.
|
Patients will be treated with the 1470nm non-ablative laser.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Live and Photographic assessment of hair loss
Time Frame: month 1
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
This is the baseline assessment.
|
month 1
|
Hair density
Time Frame: month 1
|
using Canfield HairMetrix imaging device; average number of hairs per follicular unit as baseline assessment
|
month 1
|
Hair counts
Time Frame: month 1
|
using Canfield HairMetrix imaging device; hair count per cm squared as baseline assessment
|
month 1
|
Live and Photographic assessment of hair loss
Time Frame: Month 2
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
|
Month 2
|
Live and Photographic assessment of hair loss
Time Frame: Month 3
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
|
Month 3
|
Live and Photographic assessment of hair loss
Time Frame: Month 6
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
|
Month 6
|
Live and Photographic assessment of hair loss
Time Frame: Month 9
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
|
Month 9
|
Live and Photographic assessment of hair loss
Time Frame: Month 12
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
|
Month 12
|
Live and Photographic assessment of hair loss
Time Frame: Month 15
|
GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density.
A score of zero represents no change.
|
Month 15
|
Hair density
Time Frame: Month 6
|
using Canfield HairMetrix imaging device; average number of hairs per follicular unit
|
Month 6
|
Hair density
Time Frame: Month 9
|
using Canfield HairMetrix imaging device; average number of hairs per follicular unit
|
Month 9
|
Hair density
Time Frame: Month 12
|
using Canfield HairMetrix imaging device; average number of hairs per follicular unit
|
Month 12
|
Hair density
Time Frame: Month 15
|
using Canfield HairMetrix imaging device; average number of hairs per follicular unit
|
Month 15
|
Hair counts
Time Frame: month 6
|
using Canfield HairMetrix imaging device; hair count per cm squared
|
month 6
|
Hair counts
Time Frame: month 9
|
using Canfield HairMetrix imaging device; hair count per cm squared
|
month 9
|
Hair counts
Time Frame: month 12
|
using Canfield HairMetrix imaging device; hair count per cm squared
|
month 12
|
Hair counts
Time Frame: month 15
|
using Canfield HairMetrix imaging device; hair count per cm squared
|
month 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Satisfaction
Time Frame: months 1
|
|
months 1
|
Subject Satisfaction
Time Frame: month 2
|
|
month 2
|
Subject Satisfaction
Time Frame: month 3
|
|
month 3
|
Subject Satisfaction
Time Frame: month 6
|
|
month 6
|
Subject Satisfaction
Time Frame: month 9
|
|
month 9
|
Subject Satisfation
Time Frame: month 12
|
|
month 12
|
Subject Satisfaction
Time Frame: month 15
|
|
month 15
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kseniya Kobets, MD, Albert Einstein College of Medicine Montefiore Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-14192
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgenetic Alopecia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
Pelage Pharmaceuticals, Inc.Not yet recruitingAndrogenetic Alopecia
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Indonesia UniversityRecruiting
-
Cassiopea SpAICON Clinical Research; Canfield Scientific Inc.; Ergomed PLC; Pharmapace IncRecruitingAlopecia, AndrogeneticGermany, United States, Poland
-
University of ArizonaTransdermal Cap, Inc.Recruiting
-
Gregory L Smith, MD, MPHRecruitingAndrogenetic AlopeciaUnited States
Clinical Trials on Sciton HALO 1470nm Non-ablative laser
-
Albert Einstein College of MedicineRecruitingHyperpigmentation | Acne Scars - Mixed Atrophic and Hypertrophic | Laser-Induced HyperpigmentationUnited States
-
Bispebjerg HospitalCompleted
-
The Cleveland ClinicTerminatedAbdominoplasty ScarsUnited States
-
Bispebjerg HospitalCompleted
-
Massachusetts General HospitalUnknown
-
King's College Hospital NHS TrustAlexandra Hospital, Athens, GreeceCompleted
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hangang Sacred Heart HospitalNational Research Foundation of KoreaNot yet recruitingStem Cell Media | Hypertrophic Scar | Regeneration
-
Thaís Hofmann CachafeiroUnknown
-
Lumenis Be Ltd.Active, not recruiting